glp-1 drug novo nordisk promotes new receptor agonist to fight diabetes, obesity < Pharma < Article Novo Nordisk said on Tuesday

Novo Nordisk reported the results from the STEP 1 extension trial on the impact of treatment withdrawal, which found that one year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss

A study using the Control of Eating Questionnaire (CoEQ) has reported that semaglutide treatment reduced hunger, appetite, and interest in high-palatability foods while also diminishing the pleasure of eating [17]

CrossRef Laursen TM, Musliner KL, Benros ME, et al

Forty-four percent of firms with 1,000 to 4,999 workers, and 59% of firms with 5,000 or more workers, say that the use of these medications for weight loss was higher than expected

Beyond standard metabolic monitoring (weight, blood pressure, glucose, lipids), providers should regularly assess binge eating frequency, eating disorder cognitions, mood symptoms, and quality of life